SCHEMBL29133710

SCHEMBL29133710

N#Cc1cnc2ccc(-c3cccnc3)cc2c1NCCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.52
CYP3A4 P08684 7/20 0.52
ALDH1A1 P00352 6/20 0.52
HSD17B10 Q99714 6/20 0.52
CLK4 Q9HAZ1 6/20 0.52
CYP2C19 P33261 5/20 0.52
HIF1A Q16665 5/20 0.52
CYP2D6 P10635 4/20 0.52
LMNA P02545 4/20 0.52
MAPK1 P28482 3/20 0.52
USP2 O75604 2/20 0.52
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
KDM4E B2RXH2 3/20 0.47
HPGD P15428 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP2C9 P11712 1/20 0.46
PDE5A O76074 2/20 0.46
CCNC P24863 2/20 0.46
CDK8 P49336 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29133738 0.87 CCNC (0.47) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL29133767 0.86 EGFR (0.44) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL29133731 0.84 EGFR (0.63) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL29133717 0.84 EGFR (0.50) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL29133761 0.83 EGFR (0.51) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL29133770 0.82 PIK3CA (0.54) EGFRSRCABL1FLT1KDR
SCHEMBL29133790 0.82 EGFR (0.42) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL29133722 0.82 MELK (0.54) CCNCCDK8EGFRSRCABL1
SCHEMBL29133698 0.82 MELK (0.54) CCNCCDK8EGFRSRCABL1
SCHEMBL29133766 0.81 CCNC (0.57) LMNACCNCCDK8EGFRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117295716-A Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors 麦克尼斯迪克治疗有限公司 2023-12-26 CN disclosed